Isoniazid orally dissolving strip - Oak Therapeutics

Drug Profile

Isoniazid orally dissolving strip - Oak Therapeutics

Alternative Names: INH ODS

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oak Therapeutics
  • Class Antibacterials; Antituberculars; Carboxylic acids; Hydrazines; Isonicotinic acids; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 23 Aug 2017 Oak Therapeutics plans to apply for SBIR phase II grant for isoniazid oral dissolvable strip development
  • 01 Oct 2016 Oak Therapeutics receives phase I SBIR grant from National Institute for Allergens and Infectious Diseases for isoniazid oral dissolvable strip development in Tuberculosis
  • 01 May 2016 Preclinical trials in Tuberculosis (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top